Open Access

Examination of the differences between sulforaphane and sulforaphene in colon cancer: A study based on next‑generation sequencing

  • Authors:
    • Lei Gao
    • Fengying Du
    • Jinshen Wang
    • Yuhua Zhao
    • Junhua Liu
    • Da Cai
    • Xiao Zhang
    • Yutao Wang
    • Shuqiu Zhang
  • View Affiliations

  • Published online on: August 1, 2021     https://doi.org/10.3892/ol.2021.12951
  • Article Number: 690
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sulforaphane and sulforaphene are isothiocyanate compounds derived from cruciferous vegetables that have demonstrated antiproliferative properties against colon cancer. However, the underlying mechanism of action of these two compounds has yet to be elucidated. The aim of the present study was to examine the effects of sulforaphane and sulforaphene on colon cancer using next‑generation sequencing (NGS). The SW480 colon cancer cell line was cultured with 25 µmol/l sulforaphane or sulforaphene. Total RNA was extracted from the cells following 48 h of incubation with these compounds, and NGS was performed. Pearson's correlation and principal component analyses were performed on the NGS data in order to determine sample homogeneity followed by hierarchical clustering, chromosomal location, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. A total of 873 probes in the sulforaphene group were differentially expressed compared with the control group. Similarly, 959 probes in the sulforaphane group were differentially expressed compared with the control group. The differentially expressed genes were dispersed on the chromosomes, across 22 pairs of autosomes, as well as the X and Y chromosomes. GO and KEGG analyses demonstrated that both drugs affected the ‘p53 signaling pathway’, ‘MAPK signaling pathway’, ‘FOXO signaling pathway’ and ‘estrogen signaling pathway’, while ‘Wnt signaling pathway’ was enriched in the sulforaphane group, and ‘ubiquitin mediated proteolysis’ and ‘estrogen signaling pathway’ in the sulforaphene group. Thus, sulforaphane and sulforaphene exhibited similar biological activities on colon cancer cells. Sulforaphane and sulforaphene may be associated with Wnt and estrogen signaling, respectively.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 22 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao L, Du F, Wang J, Zhao Y, Liu J, Cai D, Zhang X, Wang Y and Zhang S: Examination of the differences between sulforaphane and sulforaphene in colon cancer: A study based on next‑generation sequencing. Oncol Lett 22: 690, 2021.
APA
Gao, L., Du, F., Wang, J., Zhao, Y., Liu, J., Cai, D. ... Zhang, S. (2021). Examination of the differences between sulforaphane and sulforaphene in colon cancer: A study based on next‑generation sequencing. Oncology Letters, 22, 690. https://doi.org/10.3892/ol.2021.12951
MLA
Gao, L., Du, F., Wang, J., Zhao, Y., Liu, J., Cai, D., Zhang, X., Wang, Y., Zhang, S."Examination of the differences between sulforaphane and sulforaphene in colon cancer: A study based on next‑generation sequencing". Oncology Letters 22.4 (2021): 690.
Chicago
Gao, L., Du, F., Wang, J., Zhao, Y., Liu, J., Cai, D., Zhang, X., Wang, Y., Zhang, S."Examination of the differences between sulforaphane and sulforaphene in colon cancer: A study based on next‑generation sequencing". Oncology Letters 22, no. 4 (2021): 690. https://doi.org/10.3892/ol.2021.12951